Nutrigenomics ingredient
This article was originally published in The Tan Sheet
Executive Summary
WellGen's black tea extract product, WG0401, received a patent covering uses of the product for arthritis, inflammation and cancer, the biotech firm states July 10. The firm says it developed the ingredient through nutrigenomics - the study of how nutrients affect gene expression. "We believe WG0401 is the first nutrigenomics-developed ingredient to be commercialized for consumer application," states WellGen CEO, Kathleen P. Mullinix. The product will be marketed to the supplement industry as a functional food ingredient aimed at promoting joint health and comfort, anti-aging and immune-defense support as well as contributing to cardiovascular health, the company says. WellGen is in the process of finalizing a distribution agreement with Charles Bowman and Company to facilitate its entry into the marketplace, the firm says. The North Brunswick, N.J.-based firm announced earlier in the year it anticipates WG0401 will hit the market mid-year (1"The Tan Sheet" May 28, 2007, p. 14)...